Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFIR02_Breast: Genomic-Guided Therapy in Metastatic Breast Cancer
NCT02299999Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Apr 2014
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vistusertib, fexagratinib, capivasertib, sapitinib, selumetinib and 4 more in breast cancer (4 arms), sponsored by Unicancer. Primary endpoint: Progression-Free Survival at 16 months. Started Apr 2014; status: active, not recruiting.
02
Drugs
vistusertibfexagratinibcapivasertibsapitinibselumetinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02299999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299999.